Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 6, 2013, Pages 995-1003

  Bechmann, Troels ^a,b   Andersen, Rikke Fredslund ^b   Pallisgaard, Niels ^b   Madsen, Jonna Skov ^a,b   Maae, Else ^b   Jakobsen, Erik Hugger ^b   Bak Jylling, Anne Marie ^c   Steffensen, Karina Dahl ^c   Jakobsen, Anders ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b LILLEBAELT HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Breast cancer; Cell free DNA; HER2 amplification; Neoadjuvant chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DNA; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; PACLITAXEL; TRASTUZUMAB;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CELL FREE SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION REGULATION; HER2 GENE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LOADING DRUG DOSE; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MAMMOGRAPHY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL MASTECTOMY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84878334570     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1413-5     Document Type: Article

References (38)

1. Andersen RF, Spindler KLG, Jakobsen A, Pallisgaard N (2012) Plasma is superior to serum for cfDNA mutation detection and monitoring. Eur J Cancer 48(suppl. 6): 148-149 Ref Type: Abstract
2. Anker P, Mulcahy H, Chen XQ, Stroun M (1999) Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 18:65-73
3. Bergqvist J, Ohd JF, Smeds J, Klaar S, Isola J, Nordgren H, Elmberger GP, Hellborg H, Bjohle J, Borg AL, Skoog L, Bergh J (2007) Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. Ann Oncol 18:845-850
4. Catarino R, Ferreira MM, Rodrigues H, Coelho A, Nogal A, Sousa A, Medeiros R (2008) Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol 27:415-421
5. Egervari K, Toth J, Nemes Z, Szollosi Z (2009) An alternative and reliable real-time quantitative PCR method to determine HER2/neu amplification in breast cancer. Appl Immunohistochem Mol Morphol 17:247-254
6. Fujita N, Nakayama T, Yamamoto N, Kim SJ, Shimazu K, Shimomura A, Maruyama N, Morimoto K, Tamaki Y, Noguchi S (2012) Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients. Oncology 83:273-282
7. Gal S, Fidler C, Lo YM, Taylor M, Han C, Moore J, Harris AL, Wainscoat JS (2004) Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR. Br J Cancer 90:1211-1215
8. Galeazzi M, Morozzi G, Piccini M, Chen J, Bellisai F, Fineschi S, Marcolongo R (2003) Dosage and characterization of circulating DNA: present usage and possible applications in systemic autoimmune disorders. Autoimmun Rev 2:50-55
9. Gong B, Xue J, Yu J, Li H, Hu H, Yen H, Hu J, Dong Q, Chen F (2012) Cell-free DNA in blood is a potential diagnostic biomarker of breast cancer. Oncol Lett 3:897-900
10. Holdenrieder S, Burges A, Reich O, Spelsberg FW, Stieber P (2008) DNA integrity in plasma and serum of patients with malignant and benign diseases. Ann N Y Acad Sci 1137:162-170
11. Huang ZH, Li LH, Hua D (2006) Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett 243:64-70
12. Koffler D, Agnello V, Winchester R, Kunkel HG (1973) The occurrence of single-stranded DNA in the serum of patients with systemic lupus erythematosus and other diseases. J Clin Invest 52:198-204
13. Kohler C, Radpour R, Barekati Z, Asadollahi R, Bitzer J, Wight E, Burki N, Diesch C, Holzgreve W, Zhong XY (2009) Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer 8:105. doi: 10.1186/1476-4598-8-105
14. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37:646-650
15. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281
16. Mandel P, Metais P (1948) Les acides nucleiques du plasma sanguin chez l'homme. C R Seances Soc Biol Fil 142:241-243
17. Page K, Hava N, Ward B, Brown J, Guttery DS, Ruangpratheep C, Blighe K, Sharma A, Walker RA, Coombes RC, Shaw JA (2011) Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer 104:1342-1348
18. Pathak AK, Bhutani M, Kumar S, Mohan A, Guleria R (2006) Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 52:1833-1842
19. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ (2000) Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651-3664
20. Payne RE, Hava NL, Page K, Blighe K, Ward B, Slade M, Brown J, Guttery DS, Zaidi SA, Stebbing J, Jacob J, Yague E, Shaw JA, Coombes RC (2012) The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy. Br J Cancer 106:375-382
21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672
22. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE Jr, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684
23. Schlemmer BO, Sorensen BS, Overgaard J, Olsen KE, Gjerdrum LM, Nexo E (2004) Quantitative PCR-new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization. Scand J Clin Lab Invest 64:511-522
24. Schwarzenbach H, Muller V, Milde-Langosch K, Steinbach B, Pantel K (2011) Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease. Mol BioSyst 7:2848-2854
25. Shaw JA, Smith BM, Walsh T, Johnson S, Primrose L, Slade MJ, Walker RA, Coombes RC (2000) Microsatellite alterations plasma DNA of primary breast cancer patients. Clin Cancer Res 6:1119-1124
26. Shaw JA, Page K, Blighe K, Hava N, Guttery D, Ward B, Brown J, Ruangpratheep C, Stebbing J, Payne R, Palmieri C, Cleator S, Walker RA, Coombes RC (2012) Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res 22:220-231
27. Slamon DJ (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
28. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
29. Sorensen BS, Mortensen LS, Andersen J, Nexo E (2010) Circulating HER2 DNA after trastuzumab treatment predicts survival and response in breast cancer. Anticancer Res 30:2463-2468
30. Steinman CR (1975) Free DNA in serum and plasma from normal adults. J Clin Invest 56:512-515
31. Swystun LL, Mukherjee S, Liaw PC (2011) Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. J Thromb Haemost 9:2313-2321
32. Tse C, Brault D, Gligorov J, Antoine M, Neumann R, Lotz JP, Capeau J (2005) Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients. Clin Chem 51:1093-1101
33. Untch M, Fasching PA, Konecny GE, Hasmuller S, Lebeau A, Kreienberg R, Camara O, Muller V, du Bois A, Kuhn T, Stickeler E, Harbeck N, Hoss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29:3351-3357
34. von Minckwitz G, Loibl S, Maisch A, Untch M (2011) Lessons from the neoadjuvant setting on how best to choose adjuvant therapies. Breast 20(Suppl 3):S142-S145
35. Weigel MT, Dowsett M (2010) Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 17:R245-R262
36. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145
37. Zanetti-Dallenbach R, Wight E, Fan AX, Lapaire O, Hahn S, Holzgreve W, Zhong XY (2008) Positive correlation of cell-free DNA in plasma/serum in patients with malignant and benign breast disease. Anticancer Res 28:921-925
38. Zhong XY, Ladewig A, Schmid S, Wight E, Hahn S, Holzgreve W (2007) Elevated level of cell-free plasma DNA is associated with breast cancer. Arch Gynecol Obstet 276:327-331